BioMarin Pharmaceuticals
BMRN
BMRN
438 hedge funds and large institutions have $15.8B invested in BioMarin Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 150 increasing their positions, 145 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
1.4% more ownership
Funds ownership: 99.72% → 101.12% (+1.4%)
3% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 145
3% less capital invested
Capital invested by funds: $16.3B → $15.8B (-$449M)
Holders
438
Holding in Top 10
12
Calls
$208M
Puts
$155M
Top Buyers
| 1 | +$150M | |
| 2 | +$83.6M | |
| 3 | +$61.5M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$59.9M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$58M |
Top Sellers
| 1 | -$25.5B | |
| 2 | -$183M | |
| 3 | -$65.1M | |
| 4 |
O
OrbiMed
New York
|
-$57.4M |
| 5 |
Jennison Associates
New York
|
-$45M |